Skip to main content

Advertisement

Table 6 Serum clinical safety markers, part III

From: Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Variable T1 T2 T3 Time*group Time*group*gender
Serum protein (g/dL)
 PLA 7.0 ± 0.4 6.8 ± 0.4 7.0 ± 0.4 Time p= 0.011 G*T*Ge p = 0.97
 LD 7.0 ± 0.5 6.8 ± 0.4 7.0 ± 0.4 G*T p= 0.006
 HD 7.2 ± 0.4 7.0 ± 0.5 6.9 ± 0.3
Albumin (g/dL)
 PLA 4.6 ± 0.4 4.4 ± 0.4 4.5 ± 0.4 Time p= 0.023 G*T*Ge p = 0.67
 LD 4.5 ± 0.3 4.5 ± 0.3 4.6 ± 0.3 G*T p = 0.17
 HD 4.5 ± 0.3 4.5 ± 0.3 4.4 ± 0.2
Globulin (g/dL)
 PLA 2.5 ± 0.3 2.4 ± 0.3 2.5 ± 0.2 Time p = 0.15 G*T*Ge p = 0.85
 LD 2.4 ± 0.4 2.3 ± 0.3 2.5 ± 0.3 G*T p = 0.10
 HD 2.6 ± 0.4 2.5 ± 0.4 2.4 ± 0.4
Albumin/Globulin
 PLA 1.9 ± 0.3 1.9 ± 0.3 1.9 ± 0.3 Time p = 0.76 G*T*Ge p = 0.72
 LD 1.9 ± 0.3 1.9 ± 0.3 1.9 ± 0.2 G*T p = 0.66
 HD 1.8 ± 0.4 1.8 ± 0.4 1.8 ± 0.3
Bilirubin (mg/dL)
 PLA 0.7 ± 0.3 0.7 ± 0.4 0.8 ± 0.5 Time p = 0.84 G*T*Ge p = 0.40
 LD 0.7 ± 0.3 0.7 ± 0.3 0.6 ± 0.3 G*T p = 0.44
 HD 0.7 ± 0.3 0.7 ± 0.3 0.6 ± 0.3
ALP (IU/L)
 PLA 58 ± 17 57 ± 15 58 ± 15 Time p = 0.47 G*T*Ge p = 0.36
 LD 53 ± 11 55 ± 12 57 ± 12 G*T p = 0.25
 HD 65 ± 13 60 ± 15 62 ± 13
AST (IU/L)
 PLA 21 ± 6 19 ± 5 20 ± 4 Time p = 0.12 G*T*Ge p = 0.66
 LD 19 ± 5 18 ± 4 20 ± 7 G*T p = 0.81
 HD 20 ± 6 18 ± 6 20 ± 7
ALT (IU/L)
 PLA 17 ± 7 17 ± 6 17 ± 6 Time p = 0.34 G*T*Ge p = 0.45
 LD 17 ± 7 17 ± 8 23 ± 24 G*T p = 0.19
 HD 19 ± 8 17 ± 12 17 ± 6
  1. Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
  2. Symbols: , different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed